FPR2 receptor agonist aptamers and uses thereof. The present invention relates to FPR2 receptor agonist aptamers and uses thereof. The present invention relates to a nucleic acid aptamer with the ability to specifically bind to the FPR2 receptor and activate said FPR2 receptor, which comprises a nucleotide sequence with a sequence identity of at least 70% with the sequence SEQ ID NO : 1, SEQ ID NO: 2 or SEQ ID NO: 3. (Machine-translation by Google Translate, not legally binding)
1. A nucleic acid aptamer which is able to specifically bind to the FPR2 receptor and activate said FPR2 receptor, comprising a nucleotide sequence with a sequence identity of at least 70% with the sequence SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3. 2. Aptamer according to claim 1, wherein the nucleotide sequence has a sequence identity of, at least 80, 90, 95, 96, 97, 98 or 99% with the sequence SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3. 3. Aptamer according to claim 1 or 2, wherein the nucleotide sequence has a sequence identity of 100% with the sequence SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3. 4. Aptamer according to any one of claims 1 to 3, wherein the FPR2 receptor is the human FPR2 receptor. 5. Aptamer according to any one of claims 1 to 4, wherein the nucleic acid is DNA. 6. A complex comprising an aptamer according to any one of claims 1 to 5 and a functional group. 7. Complex according to claim 6, wherein the functional group is a detectable reagent, a drug or a nanoparticle. 8. A pharmaceutical composition comprising an aptamer according to any one of claims 1 to 5, and/or a complex according to claim 6 or 7, together with a pharmaceutically acceptable carrier, excipient or vehicle. 9. In vitro use of an aptamer according to any one of claims 1 to 5, or a complex according to claim 6 or 7, to detect the FPR2 receptor. 10. Use according to claim 9, wherein the detection of the FPR2 receptor is carried out by means of a method selected from the group consisting of ELONA, aptacytochemistry, aptahistochemistry and flow cytometry. 11. In vitro use of an aptamer according to any one of claims 1 to 5, or a complex according to claim 6 or 7, to activate the FPR2 receptor. 12. In vitro method for the detection of the FPR2 receptor in an isolated biological sample from a subject comprising (a) contacting said sample with an aptamer according to any one of claims 1 to 5, or a complex according to claim 6 or 7, (b) separating the aptamer or complex which is not bound to the FPR2 receptor, and (c) detecting the presence of the aptamer or complex which is bound to the FPR2 receptor present in the sample. 13. The method according to claim 12, wherein the detection is carried out by means of fluorescence. 14. In vitro method to activate the FPR2 receptor in an isolated biological sample from a subject comprising contacting said sample comprising the FPR2 receptor with an aptamer according to any one of claims 1 to 5, or a complex according to claim 6 or 7, under suitable conditions to activate the FPR2 receptor. 15. Method according to any one of claims 12 to 14, wherein the subject is a human. 16. Method according to any one of claims 12 to 15, wherein the isolated biological sample is blood, plasma, serum or cerebrospinal fluid. 17. An aptamer according to any one of claims 1 to 5, or a complex according to claim 6 or 7, or a pharmaceutical composition according to claim 8, for use in treating a wound. 18. An aptamer according to any one of claims 1 to 5, or a complex according to claim 6 or 7, or a pharmaceutical composition according to claim 8, for use in the prevention and/or treatment of diseases characterised by a decrease in the expression of the FPR2 receptor, and/or a decrease in the activation of the FPR2 receptor and/or an absence of the natural ligand of the FPR2 receptor and/or a low amount of the natural ligand of the FPR2 receptor with regard to the amount of natural ligand in a subject under normal health conditions or healthy. 19. Aptamer, complex or composition for use according to claim 18, wherein the disease is selected from the group consisting of cancer, an autoimmune disease, an inflammatory disease, a neurodegenerative disease, a cardiovascular disease, an infectious disease, an eye disease and an epithelial disease. 20. Aptamer, complex or composition for use according to claim 19, wherein the epithelial disease is dystrophic epidermolysis bullosa.